Urological cancer surgery.
Precision. No compromises.

Dr. Nitin treats the full spectrum of urological cancers: kidney cancer (renal cell carcinoma), bladder cancer (transitional cell carcinoma), prostate cancer, testicular cancer, and adrenal tumours. He also manages upper-tract urothelial cancers (ureteric and renal pelvis tumours), which are less common and require specialised expertise. For each cancer type, the treatment options - surgery, surveillance, or a combination with oncology - are discussed in detail at consultation.

Yes. Dr. Nitin Shrivastava performs robotic-assisted surgery using the Da Vinci Surgical System at Apollo Hospital Gurugram. For kidney cancer, robotic partial nephrectomy (removing only the tumour, preserving the rest of the kidney) is the gold-standard approach when technically feasible. For prostate cancer, robotic radical prostatectomy offers precise removal with better preservation of urinary control and sexual function compared to open surgery. Robotic surgery means smaller cuts, less blood loss, and faster return to normal life.

Not always - it depends on size, appearance on scan, your age, and overall health. Small kidney tumours (under 4 cm in many patients) can sometimes be monitored on active surveillance or treated with ablation rather than surgery. Tumours that are larger, growing, or have features suspicious for aggressive cancer typically need prompt surgery. The important thing is not to delay the assessment: a CT or MRI with contrast gives us a clear picture within days, and we will walk you through the findings and the options.

Blood in the urine - even once, even painless - is the cardinal warning sign of bladder cancer and should never be attributed to a UTI without investigation. Urinary urgency, frequency, and burning that does not resolve with antibiotics can also indicate bladder tumour. Risk is higher in smokers, those with occupational chemical exposure (dyes, rubber), and those over 50. A flexible cystoscopy (camera into the bladder under local anaesthetic) is the definitive investigation and can be arranged promptly.

Localised prostate cancer is confined within the prostate gland and is potentially curable with surgery (radical prostatectomy) or radiotherapy. Locally advanced prostate cancer has spread just beyond the prostate capsule but not to distant organs. Metastatic prostate cancer has spread to lymph nodes, bone, or other organs - at this stage, the treatment goal shifts from cure to long-term control with hormone therapy (ADT) and, increasingly, novel agents. PSA level, Gleason score from biopsy, and staging scans together determine which category a patient falls into.

This depends entirely on the cancer type, stage, and pathology of the removed specimen. For kidney cancer, surgery alone is often sufficient for localised disease; adjuvant (post-surgery) therapies are considered for high-risk cases. For bladder cancer, neoadjuvant chemotherapy before surgery and adjuvant immunotherapy are increasingly standard for muscle-invasive disease. For prostate cancer, adjuvant radiotherapy may be advised if the specimen shows certain high-risk features. Dr. Nitin works closely with a urological oncology multidisciplinary team to coordinate any additional treatments.

Robotic surgery dramatically shortens recovery compared to open surgery. After robotic kidney surgery (partial or radical nephrectomy), most patients are discharged within 2–3 days and return to desk work in 2–3 weeks. After robotic prostatectomy, hospital stay is 1–2 days with a urinary catheter for 7–10 days; desk work is typically possible within 2–3 weeks. Full physical recovery and return to strenuous activity takes 4–6 weeks for most patients. Individual timelines depend on age, fitness, and whether any complications occur.